SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AleAnna, Inc. operates as a technology-driven energy company, which engages in supplying low-carbon natural gas and renewable natural gas to Italy. The company was founded in 2007 and is headquartered in Dallas, TX.

AleAnna Inc. - Ordinary Shares - Class A

AleAnna Inc. is seeing intense investor focus as geopolitical instability in the Middle East disrupts global LNG supplies, positioning the company as a key supplier for energy-dependent European markets. The community is actively debating the stock's potential for a short squeeze amid high borrow rates and low float, while closely monitoring technical price action and potential energy infrastructure developments.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is facing intense backlash and bearish sentiment from investors following the announcement of a reverse stock split, with many in the community viewing the move as a "kiss of death" for the struggling streaming platform. Discussions are heavily focused on the company's lack of key sports networks, dwindling subscriber confidence, and frustration toward leadership, leading many traders to actively initiate or hold short positions.

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008, and is headquartered in Newton, MA.

Karyopharm Therapeutics Inc

Karyopharm Therapeutics is trending as investors digest mixed results from its Phase 3 SENTRY trial in myelofibrosis, which met spleen volume reduction goals but missed on key symptom endpoints. Community discourse is highly polarized, with some highlighting the strong overall survival signal as a potential path for future regulatory success, while others express deep frustration over the company's financial runway and recent private placement deals.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as a highly speculative, low-cap meme coin that has polarized the community, with some traders touting its potential for explosive gains while others warn it is a classic pump-and-dump scheme. Discussion centers on its rapid price volatility, accessibility via DEX platforms, and ongoing debate over whether its current price action reflects genuine accumulation or manipulative tactics by top holders.

Cantor Equity Partners II, Inc. is a blank check company. The company was founded on November 11, 2020 and is headquartered in New York, NY

Cantor Equity Partners II Inc. - Ordinary Shares - Class A

Cantor Equity Partners II Inc

Investors are closely tracking Cantor Equity Partners II as it nears its business combination with Securitize, the infrastructure provider behind major institutional tokenization projects like BlackRock's BUIDL fund. Market participants are treating the stock as a pure-play opportunity for the real-world asset (RWA) tokenization sector, with many discussing the long-term growth potential and institutional backing from major financial players.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund (VCX) is seeing intense volatility and record-high trading volume as retail investors react to its direct exposure to high-profile private AI firms like OpenAI, Anthropic, and SpaceX. While bullish sentiment is driven by the fund's unique access to these sought-after holdings, many market participants are actively debating the sustainability of its current market price compared to its intrinsic net asset value, frequently comparing the situation to previous low-float 'pump and dump' market events.

Li Auto, Inc. engages in the design, development, manufacture, and sale of premium smart electric vehicles. Its products include Li MEGA, a high-tech flagship family MPV, Li L9, a six-seat flagship family SUV, and Li L8, a six-seat premium family SUV, and Li L7, a five-seat flagship family SUV. The firm also offers in-house development efforts on its proprietary range extension system, next-generation electric vehicle technology, and smart vehicle solutions. The company was founded by Xiang Li in April 2015 and is headquartered in Beijing, China.

Li Auto Inc - ADR

Li Auto is trending as investors react to the company's newly authorized $1 billion share repurchase program, which will be valid through March 2027. While some market participants interpret the buyback as a sign of management's confidence and a potential boost to earnings per share, others remain focused on the company's valuation struggles, intense competition in the Chinese EV market, and ongoing debates regarding the efficacy of its charging technology compared to battery-swapping alternatives.

Smithfield Foods, Inc. operates as a meat-processing company. The firm processes and produces pork and hog. Its brands include Smithfield, Eckrich, Nathan's Famous, Farmland, and Armour. The company was founded by Joseph Williamson Luter, Sr. and Joseph Williamson Luter, Jr. in 1936 and is headquartered in Smithfield, VA.

Smithfield Foods, Inc.

Smithfield Foods Inc.

Smithfield Foods is trending as investors react to the companys recent earnings beat, which showcased strong growth in the packaged meats segment and a dividend increase. The community is actively discussing the stock's long-term potential, including its recent acquisition of Nathan's Famous and its strategic positioning in the protein sector despite ongoing debates surrounding industry ownership.

NETGEAR, Inc. engages in the provision of networking technologies for businesses, homes, and service providers. It operates through the Connected Home and NETGEAR for Business segments. The Connected Home segment offers WiFi networking solutions such as 4G/5G mobile products, WiFi 7 Tri-band and Quad-band mesh systems and routers, WiFi 6E, WiFi 6, and subscription services. The NETGEAR for Business segment consists of networking solutions, including switches, routers, access points, software, and AV over IP technologies. The company was founded by Patrick C. S. Lo and Mark G. Merrill on January 8, 1996, and is headquartered in San Jose, CA.

Netgear Inc

Netgear is seeing significant market attention as U.S. regulators take action against foreign-made routers, fueling community discussion regarding the company's competitive standing and potential market share gains. While traders debate the stock's turnaround potential and its exposure to ongoing supply chain and geopolitical risks, some investors are highlighting the company's valuation relative to its cash position as a key point of interest.

Concentrix Corp. engages in the provision of customer experience solutions and technology. The company was founded in 1973 and is headquartered in Newark, CA.

Concentrix Corp.

Concentrix Corporation

Concentrix is currently in focus following a volatile earnings report that missed bottom-line estimates and included a downward revision to its annual guidance, prompting significant price fluctuations. While the company continues to navigate margin pressures and client demand volatility, the community is actively debating its valuation as a potential AI-integrated bargain versus the risks posed by its debt levels and the long-term impact of automated AI solutions on its service business.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Keep looking at the dog IPOs $UPWK $CWBHF $PINS $RVLV $PSNL and getting interested in some of them. I&#39;ve very mindful of the turnarounds like ETSY, MTCH etc etc over the years.

Howard Lindzon

Arjun Reddy

$UPWK $CWBHF $PINS $RVLV $PSNL can be a good strategy.

StockTwits for iOS

StockTwits Web

Pinterest Inc

Upwork Inc

Revolve Group Inc - Ordinary Shares - Class A

Personalis Inc

 and getting interested in some of them. I've very mindful of the turnarounds like ETSY, MTCH etc etc over the years.

SPDR S&P Biotech ETF

ClearPoint Neuro Inc

Mike

@CompassCapital $psnl 260m market cap, 123 m cash, 0 debt, 60m rev in 2019 and 80m coming in 2020, and a new product coming in 2020...I find this trading at extreme cheap levels here

 260m market cap, 123 m cash, 0 debt, 60m rev in 2019 and 80m coming in 2020, and a new product coming in 2020...I find this trading at extreme cheap levels here

Abivax - ADR

Palvella Therapeutics Inc

TheLearningTrader

@TheLearningTrader do you think ex - VA revenues will rebound?

 do you think ex - VA revenues will rebound?

@CompassCapital they did make a new agreement with Merck, but I believe they will have more deals coming in 2020. Also, their liquid biopsy product coming up has huge potential. $4.09 cash per share, so at current price, it is a no brainer here.

 they did make a new agreement with Merck, but I believe they will have more deals coming in 2020. Also, their liquid biopsy product coming up has huge potential. $4.09 cash per share, so at current price, it is a no brainer here.

@TheLearningTrader  
 
That&#39;s right, I forgot about the biopsy. I just saw that ex-VA revs were down last quarter and assumed the worst

  
 
That's right, I forgot about the biopsy. I just saw that ex-VA revs were down last quarter and assumed the worst

@CompassCapital yep. They were down which worried investors. I think they will have an uptick in q1 and with the biopsy , I expect a rebound in 2020. They also got a new contract in September with Ava and recently a new whole genomics sequence. Target 15 by end 2020

 yep. They were down which worried investors. I think they will have an uptick in q1 and with the biopsy , I expect a rebound in 2020. They also got a new contract in September with Ava and recently a new whole genomics sequence. Target 15 by end 2020

@TheLearningTrader  
 
thanks for the info, appreciate it.

@CompassCapital no worries. Ipo expiry dec 17 next week. I expect a run after that.

 no worries. Ipo expiry dec 17 next week. I expect a run after that.